The Global Alzheimer’s Platform Foundation® (GAP) today issued a statement following the release of top-line updates from two Alzheimer’s clinical trials:
Recently, developments in two important Alzheimer’s clinical research studies were reported. The two studies were: Novo Nordisk’s Phase 3 EVOKE and EVOKE+ trials evaluating oral semaglutide, and Johnson & Johnson’s Phase 2b trial evaluating the tau-targeting antibody posdinemab. Both studies did not meet their primary endpoints.
The Global Alzheimer’s Platform Foundation® (GAP) will review the full EVOKE data when it is presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference next week and will examine Johnson & Johnson’s results once they are made publicly available.
“It is always disappointing when a trial doesn’t meet its endpoints, and two in one week is particularly challenging in the face of some of the field’s recent successes,” says John Dwyer, president of GAP. “We have been saying for years now that the only way we will find treatments and cures is by rewriting the playbook with more innovative trial designs reflecting what we have learned over the last decade.”
Dwyer reiterated GAP’s interest in partners who seek to broaden what is known about neurodegeneration. “We will continue to advance clinical trials with organizations that are persistent in their commitment to exploring any of the emerging interventions coming into the field, whether a trial looks at amyloid, tau, vascular disease, or related devices and diagnostic tests.” He continued “We are encouraged by the impact and improvement shown in Alzheimer’s-related biomarkers. Every missed end point tells us more about how to target Alzheimer’s Disease and related dementias, and we look forward to working with our research sponsors on how to improve our approach when the data is released.”
GAP wants to take this opportunity to thank the Novo Nordisk and Johnson & Johnson teams that expended so much time, talent and treasure on conducting these studies, and to express enormous gratitude for the thousands of trial participants that gave so much of their time to volunteer for these studies.